Related Experiment Video
Updated: Aug 11, 2026
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
[T lymphocyte immunotherapy in patients with cancer]
Víctor M Valdespino-Gómez1, Leticia Rocha-Zavaleta
1División de Cirugía del Hospital de Oncología CMN Siglo XXI del IMSS y División de Ciencias Biológicas y de la Salud de la Unidad Xochimilco de la UAM. valdespinov@yahoo.com
Abstract:
Several experimental developments in the last 20 years have hallmarked progress in understanding the cellular and molecular basis of the immune response to cancer. Identification of 30 tumor antigens associated from some expressed proteins in neoplastic cells are used as targets of immune response cells. Multiple studies have proved in vitro and in animal models that specific clones of lymphocytes T CD4+ and CD8+ recognize the tumoral immunogenic-oligopeptides and carry out the principal effecting phase in anti-tumor response. Positive immunomodulation of recognition and effecting phases have obtained objective anti-tumoral response in these experimental models. Similar strategies have been used in immunotherapy cancer patient clinical trails and have demonstrated partial objective responses. Current studies emphasize identification of new tumor molecular-antigens, in understanding new tumor mechanisms enabled to escape immunologic attack and in use of positive immunomodulation in patients with non-advanced cancer. Over the coming years, we will be surprised at the impact of this type of anti-tumor treatment.
Insights
Advances in cancer immunology reveal tumor antigens targeted by T lymphocytes (CD4+ and CD8+). Immunotherapy strategies show promise, with ongoing research focusing on new antigens and immune evasion mechanisms for better anti-cancer treatments.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Context:
- Significant progress in understanding cancer's immune response over the past two decades.
- Identification of approximately 30 tumor antigens expressed by neoplastic cells serves as targets for immune cells.
Purpose:
- To review the cellular and molecular basis of the immune response to cancer.
- To highlight advancements in cancer immunotherapy and future directions.
Summary:
- Studies demonstrate that specific T lymphocyte clones (CD4+ and CD8+) recognize tumor-associated antigens, mediating the anti-tumor response.
- Positive immunomodulation strategies have yielded objective anti-tumoral responses in experimental models and partial responses in clinical trials.
- Current research focuses on novel tumor antigen discovery, understanding immune escape mechanisms, and applying immunomodulation in early-stage cancer.
Impact:
- Experimental models and clinical trials show objective and partial anti-tumoral responses through immunotherapy.
- Future advancements are expected to significantly impact cancer treatment paradigms.
- Enhanced understanding of tumor-immune interactions promises more effective therapeutic strategies.
More Related Videos
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...